



165 – 10551 Shellbridge Way
Richmond, BC, V6X 2W8

BIOMARK'S ABSTRACT ACCEPTED FOR 2019 ASCO ONLINE PUBLICATION

Vancouver, British Columbia – (April 3, 2019) – BioMark Diagnostics Inc. ("BioMark") (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that the abstract submitted to the American Society of Clinical Oncology (ASCO) under Dr. Andrew Maksymiuk was accepted for online publication. The abstract was titled "Follow-up evaluation of outliers with elevated spermine-spermidine acetyltransferase-1 activity".

Rashid Ahmed, President and CEO, says, "This is an important milestone for BioMark and we are delighted with the scientific and clinical progress our team has made over the past few months. This year, ASCO received more than 6,200 abstracts, which were reviewed by their Scientific Program Committee and ASCO Leadership." The 2019 ASCO Annual Meeting will be take place May 31 – June 4, 2019 at the McCormick Place Convention Center in Chicago, Illinois. The majority of abstracts, including our abstract, will be released by ASCO on May 15, 2019, at 5:00 PM EDT on abstracts.asco.org.

About ASCO

Founded in 1964, the American Society of Clinical Oncology is the world's leading professional organization for physicians and oncology professionals caring for people with cancer. ASCO has over 45,000 members globally. For the 2019 ASCO annual meeting the focus will be on a unique global exchange of information on how to drive progress and expand the reach of quality care for all patients. Learn More about ASCO at <https://www.asco.org/about-asco>.

About BioMark Diagnostics Inc.

BioMark is developing proprietary, non-invasive, and accurate cancer diagnostic solutions which can help detect, monitor and assess treatment for cancer early and cost effectively. The technology can also be used for measuring response to treatment and potentially for serial monitoring for cancer survivors.

Further information about BioMark is available under its profile on the SEDAR website www.sedar.com and on the CSE website <https://thecse.com/>.

For further information on BioMark, please Contact:

Rashid Ahmed Bux

President & CEO

BioMark Diagnostics Inc.

Tel. 604-370-0779

Email: info@biomarkdiagnostics.com

Forward-Looking Information:

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of Biomark. Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

The CSE has not reviewed, approved or disapproved the content of this press release.